deltatrials
Completed PHASE3 INTERVENTIONAL 3-arm NCT03069365

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment (EXPEDITION-5)

A Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Renally-Impaired Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection (EXPEDITION-5)

Sponsor: AbbVie

Conditions Hepatitis C Virus (HCV)
Interventions Glecaprevir/pibrentasvir
Updated 18 times since 2017 Last updated: Feb 6, 2019 Started: Mar 28, 2017 Primary completion: Feb 20, 2018 Completion: Jun 5, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03069365, this PHASE3 trial focuses on Hepatitis C Virus (HCV) and remains completed. Sponsored by AbbVie, it has been updated 18 times since 2017, reflecting substantial change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

~Mar 2017 – ~Apr 2017 · 31 days · monthly snapshot~Apr 2017 – ~Jun 2017 · 2 months · monthly snapshot~Jun 2017 – ~Jul 2017 · 30 days · monthly snapshot~Jul 2017 – ~Aug 2017 · 31 days · monthly snapshot~Aug 2017 – ~Sep 2017 · 31 days · monthly snapshot~Sep 2017 – ~Oct 2017 · 30 days · monthly snapshot~Oct 2017 – ~Dec 2017 · 2 months · monthly snapshot~Dec 2017 – ~Jan 2018 · 31 days · monthly snapshot~Jan 2018 – ~Mar 2018 · 59 days · monthly snapshot~Mar 2018 – ~May 2018 · 2 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Apr 2019 · 9 months · monthly snapshot~Apr 2019 – ~Jan 2021 · 21 months · monthly snapshot~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

18 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Apr 2019 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 13 earlier versions

  1. Jul 2018 — Apr 2019 [monthly]

    Completed PHASE3

    Status: Active Not Recruiting → Completed

  2. Jun 2018 — Jul 2018 [monthly]

    Active Not Recruiting PHASE3

  3. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE3

  4. Mar 2018 — May 2018 [monthly]

    Active Not Recruiting PHASE3

  5. Jan 2018 — Mar 2018 [monthly]

    Active Not Recruiting PHASE3

  6. Dec 2017 — Jan 2018 [monthly]

    Active Not Recruiting PHASE3

    Status: Recruiting → Active Not Recruiting

  7. Oct 2017 — Dec 2017 [monthly]

    Recruiting PHASE3

  8. Sep 2017 — Oct 2017 [monthly]

    Recruiting PHASE3

  9. Aug 2017 — Sep 2017 [monthly]

    Recruiting PHASE3

  10. Jul 2017 — Aug 2017 [monthly]

    Recruiting PHASE3

  11. Jun 2017 — Jul 2017 [monthly]

    Recruiting PHASE3

  12. Apr 2017 — Jun 2017 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  13. Mar 2017 — Apr 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AbbVie
Data source: AbbVie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Alexandroupoli, Greece , Athens, Greece , Barcelona, Spain , Bialystok, Poland , Bologna, Italy , Boston, United States , Charlotte, United States , Edmonton, Canada , Frankfurt am Main, Germany , Hanover, Germany and 23 more locations